- Home
- LBRDP vs ZLAB Comparison
LBRDP vs ZLAB Comparison
Compare LBRDP & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBRDP
- ZLAB
- Stock Information
- Founded
- LBRDP N/A
- ZLAB 2013
- Country
- LBRDP United States
- ZLAB Cayman Islands
- Employees
- LBRDP 1900
- ZLAB N/A
- Industry
- LBRDP Cable & Other Pay Television Services
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- LBRDP Telecommunications
- ZLAB Health Care
- Exchange
- LBRDP Nasdaq
- ZLAB Nasdaq
- Market Cap
- LBRDP N/A
- ZLAB 3.5B
- IPO Year
- LBRDP N/A
- ZLAB 2017
- Fundamental
- Price
- LBRDP $24.29
- ZLAB $32.53
- Analyst Decision
- LBRDP
- ZLAB Buy
- Analyst Count
- LBRDP 0
- ZLAB 4
- Target Price
- LBRDP N/A
- ZLAB $47.37
- AVG Volume (30 Days)
- LBRDP N/A
- ZLAB 1.6M
- Earning Date
- LBRDP N/A
- ZLAB 05-08-2025
- Dividend Yield
- LBRDP N/A
- ZLAB N/A
- EPS Growth
- LBRDP N/A
- ZLAB N/A
- EPS
- LBRDP N/A
- ZLAB N/A
- Revenue
- LBRDP N/A
- ZLAB $398,988,000.00
- Revenue This Year
- LBRDP N/A
- ZLAB $45.57
- Revenue Next Year
- LBRDP N/A
- ZLAB $47.91
- P/E Ratio
- LBRDP N/A
- ZLAB N/A
- Revenue Growth
- LBRDP N/A
- ZLAB 49.59
- 52 Week Low
- LBRDP N/A
- ZLAB $15.00
- 52 Week High
- LBRDP N/A
- ZLAB $39.77
- Technical
- Relative Strength Index (RSI)
- LBRDP 49.24
- ZLAB 51.76
- Support Level
- LBRDP $23.39
- ZLAB $28.34
- Resistance Level
- LBRDP $24.29
- ZLAB $33.45
- Average True Range (ATR)
- LBRDP 0.39
- ZLAB 2.34
- MACD
- LBRDP 0.04
- ZLAB -0.02
- Stochastic Oscillator
- LBRDP 85.88
- ZLAB 61.00
About LBRDP Liberty Broadband Corporation Series A Cumulative Redeemable Preferred Stock
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.